Apopka Artificial Kidney Center in Apopka, Florida - Dialysis Center

Apopka Artificial Kidney Center is a medicare approved dialysis facility center in Apopka, Florida and it has 16 dialysis stations. It is located in Orange county at 1065 W Orange Blossom Trl, Apopka, FL, 32712. You can reach out to the office of Apopka Artificial Kidney Center at (407) 880-2121. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Apopka Artificial Kidney Center has the following ownership type - Profit. It was first certified by medicare in February, 1988. The medicare id for this facility is 102592 and it accepts patients under medicare ESRD program.

Dialysis Center Profile

NameApopka Artificial Kidney Center
Location1065 W Orange Blossom Trl, Apopka, Florida
No. of Dialysis Stations 16
Medicare ID102592
Managed ByFresenius Medical Care
Ownership TypeProfit
Late Shifts No

Contact Information


1065 W Orange Blossom Trl, Apopka, Florida, 32712
(407) 880-2121
Not Available

News Archive

Study: Antisense drugs show activity in wide range of tissues and organs

Antisense therapeutics, a class of drugs comprised of short nucleic acid sequences, can target a dysfunctional gene and silence its activity. A new study has shown that antisense drugs delivered systemically show activity in a wide range of tissues and organs, supporting their broad therapeutic potential in many disease indications, as described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Scientists suggest combinational therapy can improve treatment of solid tumors

Most, if not all, solid tumors contain regions that are not well oxygenated. Tumor cells in these regions, which are known as hypoxic regions, are usually resistant to the death-inducing effects of chemotherapeutics. But now, Caroline Dive and colleagues, at Manchester University, United Kingdom, have identified a compound that induces human cancer cells exposed to hypoxic conditions in vitro to undergo a form of cell death known as apoptosis.

Matrix receives FDA's tentative approval for novel co-packaged version of HIV/AIDS therapy

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) through the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine / Tenofovir Disoproxil Fumarate Tablets, 300 mg/300 mg, co-packaged with Nevirapine Tablets, 200 mg.

UNICEF Executive Director discusses need for commodities market for life-saving medicines

In this Forbes interview, Rahim Kanani of the Skoll World Forum speaks with UNICEF Executive Director Anthony Lake about reducing child mortality and the need for a commodities market to improve access to medicines and health care.

New designer steroid discovered in anonymously provided syringe

A previously unknown synthetic "designer" steroid has been identified as tetrahydrogestrinone (THG). Researchers working out of the UCLA Olympic Analytical Laboratory in Los Angeles synthesized and characterized the "New Chemical Entity", and proceeded to develop a rapid and accurate urine detection test for it.

Read more Medical News

› Verified 3 days ago


Map and Direction



NPI Associated with this Dialysis Facility:

Dialysis Facilities may have multiple NPI numbers. We have found possible NPI number/s associated with Apopka Artificial Kidney Center from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

NPI Number1043322894
Organization NameApopka Artificial Kidney Center
Doing Business AsBio-medical Applications Of Florida, Inc.
Address1065 W Orange Blossom Trl Apopka, Florida, 32712
Phone Number(407) 880-2121

News Archive

Study: Antisense drugs show activity in wide range of tissues and organs

Antisense therapeutics, a class of drugs comprised of short nucleic acid sequences, can target a dysfunctional gene and silence its activity. A new study has shown that antisense drugs delivered systemically show activity in a wide range of tissues and organs, supporting their broad therapeutic potential in many disease indications, as described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Scientists suggest combinational therapy can improve treatment of solid tumors

Most, if not all, solid tumors contain regions that are not well oxygenated. Tumor cells in these regions, which are known as hypoxic regions, are usually resistant to the death-inducing effects of chemotherapeutics. But now, Caroline Dive and colleagues, at Manchester University, United Kingdom, have identified a compound that induces human cancer cells exposed to hypoxic conditions in vitro to undergo a form of cell death known as apoptosis.

Matrix receives FDA's tentative approval for novel co-packaged version of HIV/AIDS therapy

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) through the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine / Tenofovir Disoproxil Fumarate Tablets, 300 mg/300 mg, co-packaged with Nevirapine Tablets, 200 mg.

UNICEF Executive Director discusses need for commodities market for life-saving medicines

In this Forbes interview, Rahim Kanani of the Skoll World Forum speaks with UNICEF Executive Director Anthony Lake about reducing child mortality and the need for a commodities market to improve access to medicines and health care.

New designer steroid discovered in anonymously provided syringe

A previously unknown synthetic "designer" steroid has been identified as tetrahydrogestrinone (THG). Researchers working out of the UCLA Olympic Analytical Laboratory in Los Angeles synthesized and characterized the "New Chemical Entity", and proceeded to develop a rapid and accurate urine detection test for it.

Read more Medical News

› Verified 3 days ago


Patient Distribution

Anemia Management

Dialysis patients with Hemoglobin data29

News Archive

Study: Antisense drugs show activity in wide range of tissues and organs

Antisense therapeutics, a class of drugs comprised of short nucleic acid sequences, can target a dysfunctional gene and silence its activity. A new study has shown that antisense drugs delivered systemically show activity in a wide range of tissues and organs, supporting their broad therapeutic potential in many disease indications, as described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Scientists suggest combinational therapy can improve treatment of solid tumors

Most, if not all, solid tumors contain regions that are not well oxygenated. Tumor cells in these regions, which are known as hypoxic regions, are usually resistant to the death-inducing effects of chemotherapeutics. But now, Caroline Dive and colleagues, at Manchester University, United Kingdom, have identified a compound that induces human cancer cells exposed to hypoxic conditions in vitro to undergo a form of cell death known as apoptosis.

Matrix receives FDA's tentative approval for novel co-packaged version of HIV/AIDS therapy

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) through the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine / Tenofovir Disoproxil Fumarate Tablets, 300 mg/300 mg, co-packaged with Nevirapine Tablets, 200 mg.

UNICEF Executive Director discusses need for commodities market for life-saving medicines

In this Forbes interview, Rahim Kanani of the Skoll World Forum speaks with UNICEF Executive Director Anthony Lake about reducing child mortality and the need for a commodities market to improve access to medicines and health care.

New designer steroid discovered in anonymously provided syringe

A previously unknown synthetic "designer" steroid has been identified as tetrahydrogestrinone (THG). Researchers working out of the UCLA Olympic Analytical Laboratory in Los Angeles synthesized and characterized the "New Chemical Entity", and proceeded to develop a rapid and accurate urine detection test for it.

Read more Medical News

› Verified 3 days ago

Dialysis Adequacy

Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.

  • Hemodialysis
    Adult patients getting regular hemodialysis at the center52
    Adult patient months included in Kt/V greater than or equal to 1.2461
    Percentage of adult patients getting regular hemodialysis at the center
    Percentage of pediatric patients getting regular hemodialysis at the center

    News Archive

    Study: Antisense drugs show activity in wide range of tissues and organs

    Antisense therapeutics, a class of drugs comprised of short nucleic acid sequences, can target a dysfunctional gene and silence its activity. A new study has shown that antisense drugs delivered systemically show activity in a wide range of tissues and organs, supporting their broad therapeutic potential in many disease indications, as described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

    Scientists suggest combinational therapy can improve treatment of solid tumors

    Most, if not all, solid tumors contain regions that are not well oxygenated. Tumor cells in these regions, which are known as hypoxic regions, are usually resistant to the death-inducing effects of chemotherapeutics. But now, Caroline Dive and colleagues, at Manchester University, United Kingdom, have identified a compound that induces human cancer cells exposed to hypoxic conditions in vitro to undergo a form of cell death known as apoptosis.

    Matrix receives FDA's tentative approval for novel co-packaged version of HIV/AIDS therapy

    Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) through the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine / Tenofovir Disoproxil Fumarate Tablets, 300 mg/300 mg, co-packaged with Nevirapine Tablets, 200 mg.

    UNICEF Executive Director discusses need for commodities market for life-saving medicines

    In this Forbes interview, Rahim Kanani of the Skoll World Forum speaks with UNICEF Executive Director Anthony Lake about reducing child mortality and the need for a commodities market to improve access to medicines and health care.

    New designer steroid discovered in anonymously provided syringe

    A previously unknown synthetic "designer" steroid has been identified as tetrahydrogestrinone (THG). Researchers working out of the UCLA Olympic Analytical Laboratory in Los Angeles synthesized and characterized the "New Chemical Entity", and proceeded to develop a rapid and accurate urine detection test for it.

    Read more Medical News

    › Verified 3 days ago

Mineral and Bone Disorder

An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Apopka Artificial Kidney Center with elevated calcium levels.

Patients with hypercalcemia56
Hypercalcemia patient months485
Hypercalcemia patients with serumcalcium greater than 10.2 mg
Patients with Serumphosphor60
Patients with Serumphosphor less than 3.5 mg/dL
Patients with Serumphosphor from 3.5 to 4.5 mg/dL
Patients with Serumphosphor from 4.6 to 5.5 mg/dL
Patients with Serumphosphor from 5.6 to 7 mg/dL
Patients with Serumphosphor greater than 7 mg/dL

News Archive

Study: Antisense drugs show activity in wide range of tissues and organs

Antisense therapeutics, a class of drugs comprised of short nucleic acid sequences, can target a dysfunctional gene and silence its activity. A new study has shown that antisense drugs delivered systemically show activity in a wide range of tissues and organs, supporting their broad therapeutic potential in many disease indications, as described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Scientists suggest combinational therapy can improve treatment of solid tumors

Most, if not all, solid tumors contain regions that are not well oxygenated. Tumor cells in these regions, which are known as hypoxic regions, are usually resistant to the death-inducing effects of chemotherapeutics. But now, Caroline Dive and colleagues, at Manchester University, United Kingdom, have identified a compound that induces human cancer cells exposed to hypoxic conditions in vitro to undergo a form of cell death known as apoptosis.

Matrix receives FDA's tentative approval for novel co-packaged version of HIV/AIDS therapy

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) through the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine / Tenofovir Disoproxil Fumarate Tablets, 300 mg/300 mg, co-packaged with Nevirapine Tablets, 200 mg.

UNICEF Executive Director discusses need for commodities market for life-saving medicines

In this Forbes interview, Rahim Kanani of the Skoll World Forum speaks with UNICEF Executive Director Anthony Lake about reducing child mortality and the need for a commodities market to improve access to medicines and health care.

New designer steroid discovered in anonymously provided syringe

A previously unknown synthetic "designer" steroid has been identified as tetrahydrogestrinone (THG). Researchers working out of the UCLA Olympic Analytical Laboratory in Los Angeles synthesized and characterized the "New Chemical Entity", and proceeded to develop a rapid and accurate urine detection test for it.

Read more Medical News

› Verified 3 days ago

Vascular Access

The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.

Patients included in arterial venous fistula and catheter summaries 58
Patient months included in arterial venous fistula and catheter summaries 368
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer

News Archive

Study: Antisense drugs show activity in wide range of tissues and organs

Antisense therapeutics, a class of drugs comprised of short nucleic acid sequences, can target a dysfunctional gene and silence its activity. A new study has shown that antisense drugs delivered systemically show activity in a wide range of tissues and organs, supporting their broad therapeutic potential in many disease indications, as described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Scientists suggest combinational therapy can improve treatment of solid tumors

Most, if not all, solid tumors contain regions that are not well oxygenated. Tumor cells in these regions, which are known as hypoxic regions, are usually resistant to the death-inducing effects of chemotherapeutics. But now, Caroline Dive and colleagues, at Manchester University, United Kingdom, have identified a compound that induces human cancer cells exposed to hypoxic conditions in vitro to undergo a form of cell death known as apoptosis.

Matrix receives FDA's tentative approval for novel co-packaged version of HIV/AIDS therapy

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) through the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine / Tenofovir Disoproxil Fumarate Tablets, 300 mg/300 mg, co-packaged with Nevirapine Tablets, 200 mg.

UNICEF Executive Director discusses need for commodities market for life-saving medicines

In this Forbes interview, Rahim Kanani of the Skoll World Forum speaks with UNICEF Executive Director Anthony Lake about reducing child mortality and the need for a commodities market to improve access to medicines and health care.

New designer steroid discovered in anonymously provided syringe

A previously unknown synthetic "designer" steroid has been identified as tetrahydrogestrinone (THG). Researchers working out of the UCLA Olympic Analytical Laboratory in Los Angeles synthesized and characterized the "New Chemical Entity", and proceeded to develop a rapid and accurate urine detection test for it.

Read more Medical News

› Verified 3 days ago

Hospitalization Rate

The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.

Standard Hospitalization Summary Ratio(SHR) YearJanuary, 2016 - December, 2016
Patients in facility's Hospitalization Summary
Hospitalization Rate in facility (Not Available)
Hospitalization Rate: Upper Confidence Limit
Hospitalization Rate: Lower Confidence Limit

News Archive

Study: Antisense drugs show activity in wide range of tissues and organs

Antisense therapeutics, a class of drugs comprised of short nucleic acid sequences, can target a dysfunctional gene and silence its activity. A new study has shown that antisense drugs delivered systemically show activity in a wide range of tissues and organs, supporting their broad therapeutic potential in many disease indications, as described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Scientists suggest combinational therapy can improve treatment of solid tumors

Most, if not all, solid tumors contain regions that are not well oxygenated. Tumor cells in these regions, which are known as hypoxic regions, are usually resistant to the death-inducing effects of chemotherapeutics. But now, Caroline Dive and colleagues, at Manchester University, United Kingdom, have identified a compound that induces human cancer cells exposed to hypoxic conditions in vitro to undergo a form of cell death known as apoptosis.

Matrix receives FDA's tentative approval for novel co-packaged version of HIV/AIDS therapy

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) through the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine / Tenofovir Disoproxil Fumarate Tablets, 300 mg/300 mg, co-packaged with Nevirapine Tablets, 200 mg.

UNICEF Executive Director discusses need for commodities market for life-saving medicines

In this Forbes interview, Rahim Kanani of the Skoll World Forum speaks with UNICEF Executive Director Anthony Lake about reducing child mortality and the need for a commodities market to improve access to medicines and health care.

New designer steroid discovered in anonymously provided syringe

A previously unknown synthetic "designer" steroid has been identified as tetrahydrogestrinone (THG). Researchers working out of the UCLA Olympic Analytical Laboratory in Los Angeles synthesized and characterized the "New Chemical Entity", and proceeded to develop a rapid and accurate urine detection test for it.

Read more Medical News

› Verified 3 days ago